Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Glioblastoma 264Glioma 109Brain Neoplasms 104Gliosarcoma 85Central Nervous System Neoplasms 64Astrocytoma 61Melanoma 46Oligodendroglioma 44Neuroblastoma 28Recurrence 22Neoplasm Metastasis 18Neoplasms 16Medulloblastoma 16Ependymoma 16Sarcoma, Ewing 13Lymphoma 13Sarcoma 12Rhabdomyosarcoma 11Neuroendocrine Tumors 11Lung Neoplasms 11Diffuse Intrinsic Pontine Glioma 10Small Cell Lung Carcinoma 9Neuroectodermal Tumors, Primitive 7Colorectal Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6Osteosarcoma 6Pinealoma 5Optic Nerve Glioma 5Choroid Plexus Neoplasms 5Carcinoma, Non-Small-Cell Lung 5

Interventions

lanreotide 1Temozolomide 1Surveys and Questionnaires 1Solutions 1Radiosurgery 1Microarray Analysis 1Injections 1Early Intervention, Educational 1Diet, Mediterranean 1Diet, Ketogenic 1DNA Methylation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Growth Hormone-Secreting Pituitary Adenoma × Temozolomide × Clear all
NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡